The associations between bullous pemphigoid and drug use: A UK case-control study

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 58-62

  Lloyd Lavery, Antonia ^a   Chi, Ching Chi ^c   Wojnarowska, Fenella ^b   Taghipour, Kathy ^d  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOOP DIURETIC AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN D; WARFARIN;

AGED; ANAMNESIS; ARTICLE; BULLOUS PEMPHIGOID; CANCER CENTER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EXPLORATORY RESEARCH; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; TERTIARY HEALTH CARE; UNITED STATES; UNIVERSITY HOSPITAL; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GREAT BRITAIN; HOSPITALS, UNIVERSITY; HUMANS; MALE; MULTIVARIATE ANALYSIS; PEMPHIGOID, BULLOUS; PHARMACEUTICAL PREPARATIONS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84873464177     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.376     Document Type: Article

References (20)

1. Baz K, Ikizoglu G, Kaya TI, Koca A. Furosemide-induced bullous pemphigoid. J Eur Acad Dermatol Venereol. 2002;16(1):81-82.
2. Lee JJ, Downham TF II. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5(6):562-564.
3. Panayiotou BN, Prasad MV, Zaman MN. Frusemide-induced bullous pemphigoid Br J Clin Pract. 1997;51(1):49-50
4. Koch CA, Mazzaferri EL, Larry JA, Fanning TS. Bullous pemphigoid after treatment with furosemide. Cutis. 1996;58(5):340-344. (Pubitemid 26384770)
5. Siddiqui MA, Zaman MN. Recurrent and chronic leg ulcers secondary to furosemidenduced bullous pemphigoid. J Am GeriatrSoc. 1995;43(10):1183-1184.
6. Castel T, Gratacos R, Castro J, Bergada E, Lecha M, Mascaro JM. Bullous pemphigoid induced byfrusemide. Clin Exp Dermatol. 1981;6(6):635-638.
7. Fellner MJ, Katz JM. Occurrence of bullous pemphigoid after furosemide therapy. Arch Dermatol. 1976;112(1):75-77
8. Chen TJ, Lai PC, Yang LC, Kuo TT, Hong HS. Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature. Am J Clin Dermatol 2009;10(3):197-200.
9. Mullins PD, Choudhury SL. Enalapril and bullous eruptions [case report]. BMJ. 1994;309(6966):1411. (Pubitemid 24351408)
10. Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol. 2005;4(6):746-748
11. Hodak E, Ben-Shetrit A, Ingber A, Sandbank M. Bullous pemphigoid: an adverse effect of ampicillin. Clin Exp Dermatol. 1990;15(1):50-52 (Pubitemid 20033886)
12. Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M. Bullous pemphigoid during long-term TNF-α blocker therapy. Dermatology. 2009;219(4) 357-358.
13. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol. 1996;132(3):272-276. (Pubitemid 26085178)
14. Bastuji-Garin S, Joly P, Lemordant P, et al; French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective casecontrol study. J Invest Dermatol. 2011;131(3):637-643.
15. Taghipour K, Chi C, Vincent A, et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010 146(11):1251-1254.
16. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 1991;30(5):307-312.
17. Langan SM, Hubbard R, Fleming K, West J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol. 2009;161(5):1149-1152.
18. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13(6):337-339. (Pubitemid 38868205)
19. Cordel N, Chosidow O, Hellot MF, et al; French Study Group of Bullous Diseases. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007;215(3):187-191 (Pubitemid 47378983)
20. Chen Y, Wu C, Lin M, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165(3):593-599